Background
FDA approval of the first long-acting injectable (LAI) antiretroviral therapy (ART) formulation opens a new era for HIV treatment. LAI ART formulations have the potential to change HIV care delivery by providing a treatment option that is discreet, long-acting, and does not require adherence to daily oral medication.
Accelerating Implementation of Long-Acting Injectables Project supports the implementation and delivery of LAI ART at eight demonstration sites in EHE jurisdictions across the US.
ALAI UP focuses on the dissemination and scale-up of activities and implementation strategies identified at demonstration sites to help facilitate the rollout of future LAI ART modalities. These activities and strategies, as well as other resources developed by our expert team, will be posted to the HIV Resource Hub.
Meet the Demonstration Sites
- Abounding Prosperity (Dallas, TX). Contact: Melissa Curry
- Baltimore City Health Department Sexual Health Clinic (Baltimore, MD). Contact: Dr. Lola Akolo
- Coastal Family Health Center (Biloxi, MS). Contact: Will Holt
- Mount Sinai Harlem Heath-Jack Martin Fund Center (New York, NY). Contact: Jesus Robles
- Positive Health Impact Center (Decatur, GA). Contact: Shin Ly
- San Antonio AIDS Foundation (San Antonio, TX). Contact: Fabriel Torres
- Sinai Infectious Disease Center (Chicago, IL). Contact: Bijou Hunt
- Sunshine Care Center, Florida Department of Health (Orlando, FL). Contact: Dr. Asim Jani
Project Contacts
Kathrine Meyers, DrPH, MS, MPP
Project Director
Columbia University Irving Medical Center Aaron Diamond AIDS Research Center
Email: kam2157@cumc.columbia.edu
Phone: 212-304-6110
Charlie Ferrusi, MPH
Project Manager
Columbia University Irving Medical Center Aaron Diamond AIDS Research Center
Email: cf2984@cumc.columbia.edu
HRSA Contacts
PO Name
Marlene Matosky, MPH, RN
PO Title
Chief, Clinical and Quality Branch
PO Email
mmatosky@hrsa.gov
Funding
Funding Mechanism: Cooperative Agreement
Recipient Organization: Columbia University Irving Medical Center
Grant number:U1SHA46532
Project Period:9/1/2022 – 8/31/2026
